Competing designs for phase I clinical trials: a review
Citations Over TimeTop 10% of 2002 papers
Abstract
Phase I clinical trials are typically small, uncontrolled studies designed to determine a maximum tolerated dose of a drug which will be used in further testing. Two divergent schools have developed in designing phase I clinical trials. The first defines the maximum tolerated dose as a statistic computed from data, and hence it is identified, rather than estimated. The second defines the maximum tolerated dose as a parameter of a monotonic dose-response curve, and hence is estimated. We review techniques from both philosophies. The goal is to present these methods in a single package, to compare them from philosophical and statistical grounds, to hopefully clear up some common misconceptions, and to make a few recommendations. This paper is not a review of simulation studies of these designs, nor does it present any new simulations comparing these designs.
Related Papers
- → Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design(2006)189 cited
- → Experimental designs for phase I and phase I/II dose-finding studies(2006)76 cited
- → Emerging innovations in clinical trial design(2015)44 cited
- Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--approaches to clinical trials design.(1990)
- → Clinical Trials: A Planning and Design Blueprint with an Emphasis on Multinational Trials.(2018)